 Home > Active Ingredient News > Drugs Articles > Gilead's oncology business could account for a third of total revenue by 2030

Gilead's oncology business could account for a third of total revenue by 2030

 Last Update: 2022-06-11
 Source: Internet
 Author: User

Tags

reference company

car therapy companies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

A few days ago, Gilead made a long-term outlook on its performance prospects

This also means that the company will need to undergo a major transformation in the future

Beyond that, Gilead sees another big payoff coming from the 20 oncology drugs under development

For investors, Gilead will gradually increase the performance of its oncology franchise, making it a third of total revenue

Previously, Gilead has partnered with dozens of biotech companies including Kite and Immunomedics

Reference source:

2.
Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Top Product

$1.6-1.65/G FOB

P-tolylacetic acid

CAS No.: 622-47-9

Industrial Grade or Medical grade

$1/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.